|
1
|
Evans LS and Hancock BW: Non-Hodgkin
lymphoma. Lancet. 362:139–146. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vose JM, Link BK, Grossbard ML, Czuczman
M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA and Fisher RI: Phase
II study of rituximab in combination with chop chemotherapy in
patients with previously untreated, aggressive non-Hodgkin’s
lymphoma. J Clin Oncol. 19:389–397. 2001.PubMed/NCBI
|
|
3
|
Salaverria I, Perez-Galan P, Colomer D and
Campo E: Mantle cell lymphoma: From pathology and molecular
pathogenesis to new therapeutic perspectives. Haematologica.
91:11–16. 2006.PubMed/NCBI
|
|
4
|
Chen R, Chubb S, Cheng T, Hawtin RE,
Gandhi V and Plunkett W: Responses in mantle cell lymphoma cells to
SNS-032 depend on the biological context of each cell line. Cancer
Res. 70:6587–6597. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frick M, Dörken B and Lenz G: New insights
into the biology of molecular subtypes of diffuse large B-cell
lymphoma and Burkitt lymphoma. Best Pract Res Clin Haematol.
25:3–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang DL, Qi FH, Xu HL, Inagaki Y, Orihara
Y, Sekimizu K, Kokudo N, Wang FS and Tang W: Apoptosis-inducing
activity of compounds screened and characterized from cinobufacini
by bioassay-guided isolation. Mol Med Rep. 3:717–722. 2010.
|
|
7
|
Wang L, Raju U, Milas L, Molkentine D,
Zhang Z, Yang P, Cohen L, Meng Z and Liao Z: Huachansu, containing
cardiac glycosides, enhances radiosensitivity of human lung cancer
cells. Anticancer Res. 31:2141–2148. 2011.PubMed/NCBI
|
|
8
|
Gomes A, Bhattacharjee P, Mishra R, Biswas
AK, Dasgupta SC and Giri B: Anticancer potential of animal venoms
and toxins. Indian J Exp Biol. 48:93–103. 2010.PubMed/NCBI
|
|
9
|
Qi F, Li A, Inagaki Y, Kokudo N, Tamura S,
Nakata M and Tang W: Antitumor activity of extracts and compounds
from the skin of the toad Bufo bufo gargarizans Cantor. Int
Immunopharmacol. 11:342–349. 2011. View Article : Google Scholar
|
|
10
|
Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP
and Pan BR: Efficacy and safety of gemcitabine-oxaliplatin combined
with huachansu in patients with advanced gallbladder carcinoma.
World J Gastroenterol. 14:5210–5216. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge
Y, Newman RA, Cohen L, Liu L, Thornton B, et al: Pilot study of
huachansu in patients with hepatocellular carcinoma, non-small-cell
lung cancer, or pancreatic cancer. Cancer. 115:5309–5318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He X, Tang J, Qiao A, Wang G, Jiang M, Liu
RH and Yao X: Cytotoxic biotransformed products from cinobufagin by
Mucor spinosus and Aspergillus Niger. Steroids. 71:392–402. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yeh JY, Huang WJ, Kan SF and Wang PS:
Effects of bufalin and cinobufagin on the proliferation of androgen
dependent and independent prostate cancer cells. Prostate.
54:112–124. 2003. View Article : Google Scholar
|
|
14
|
Takai N, Ueda T, Nishida M, Nasu K and
Narahara H: Bufalin induces growth inhibition, cell cycle arrest
and apoptosis in human endometrial and ovarian cancer cells. Int J
Mol Med. 21:637–643. 2008.PubMed/NCBI
|
|
15
|
Wang J, Jin Y, Xu Z, Zheng Z and Wan S:
Involvement of caspase-3 activity and survivin downregulation in
cinobufocini-induced apoptosis in A 549 cells. Exp Biol Med
(Maywood). 234:566–572. 2009. View Article : Google Scholar
|
|
16
|
Zhang LLJ, Qian Y, Wang Y and Shen ZX:
Cinobufacini induces the apoptosis of U937 cells and its mechanism.
Tumor. 27:341–344. 2007.
|
|
17
|
Yang HYZN, Hong YW and Yu RX: The
experimental research on cinobufacini inducing apoptosis in human
leukemia cell line HL60. Fujian J Trad Chin Med. 33:43–44.
2002.
|
|
18
|
Qi F, Li A, Zhao L, Xu H, Inagaki Y, Wang
D, Cui X, Gao B, Kokudo N, Nakata M, et al: Cinobufacini, an
aqueous extract from Bufo bufo gargarizans Cantor, induces
apoptosis through a mitochondria-mediated pathway in human
hepatocellular carcinoma cells. J Ethnopharmacol. 128:654–661.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang NYLS, Zhao W, Qin SK, Liu L and Chen
HY: Study the effect of antiangiogenesis of arsenic trioxide in
combination with cinobufacini on chick embryo choriallantoic
membrane. Chin Clin Oncol. 11:864–866. 2006.
|
|
21
|
Tao WWX: Clinical observation of huachansu
injection combined with CHOP regimen in treatment of NHL. J Med
Forum. 31:89–93. 2010.
|
|
22
|
Zheng PSZY, Dai ZX, Ding XL and Sun XH:
Effect of Huachansu injection on T-lymphocyte subgroups and natural
killer cells in patients with non-Hodgkin lymphoma. Liaoning Trad
Chin Med. 37:175–176. 2010.
|
|
23
|
Zheng B, Fiumara P, Li YV, Georgakis G,
Snell V, Younes M, Vauthey JN, Carbone A and Younes A: MEK/ERK
pathway is aberrantly active in Hodgkin disease: A signaling
pathway shared by CD30, CD40, and RANK that regulates cell
proliferation and survival. Blood. 102:1019–1027. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han KQ, Huang G, Gu W, Su YH, Huang XQ and
Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms
of bufalin on the orthotopic transplantation tumor model of human
hepatocellular carcinoma in nude mice. World J Gastroenterol.
13:3374–3379. 2007.PubMed/NCBI
|
|
25
|
Tempone AG, Pimenta DC, Lebrun I,
Sartorelli P, Taniwaki NN, de Andrade HF Jr, Antoniazzi MM and
Jared C: Antileishmanial and antitrypanosomal activity of
bufadienolides isolated from the toad Rhinella jimi parotoid
macrogland secretion. Toxicon. 52:13–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cunha Filho GA, Schwartz CA, Resck IS,
Murta MM, Lemos SS, Castro MS, Kyaw C, Pires OR Jr, Leite JR, Bloch
C Jr, et al: Antimicrobial activity of the bufadienolides
marinobufagin and telocinobufagin isolated as major components from
skin secretion of the toad Bufo rubescens. Toxicon. 45:777–782.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meng Y, Whiting P, Sik V, Rees HH and
Dinan L: Ecdysteroids and bufadienolides from Helleborus torquatus
(Ranunculaceae). Phytochemistry. 57:401–407. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Abdel-Aziz W, Jiang HY, Hickey RJ and
Malkas LH: Ara-C affects formation of cancer cell DNA synthesome
replication intermediates. Cancer Chemother Pharmacol. 45:312–319.
2000. View Article : Google Scholar
|
|
29
|
Mamelak AN and Jacoby DB: Targeted
delivery of antitumoral therapy to glioma and other malignancies
with synthetic chloro-toxin (TM-601). Expert Opin Drug Deliv.
4:175–186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fayette J, Coquard IR, Alberti L, Ranchère
D, Boyle H and Blay JY: ET-743: A novel agent with activity in soft
tissue sarcomas. Oncologist. 10:827–832. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Erba E, Bergamaschi D, Bassano L, Damia G,
Ronzoni S, Faircloth GT and D’Incalci M: Ecteinascidin-743
(ET-743), a natural marine compound, with a unique mechanism of
action. Eur J Cancer. 37:97–105. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Simoens C, Korst AE, De Pooter CM,
Lambrechts HA, Pattyn GG, Faircloth GT, Lardon F and Vermorken JB:
In vitro interaction between ecteinascidin 743 (ET-743) and
radiation, in relation to its cell cycle effects. Br J Cancer.
89:2305–2311. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Newman DJ and Cragg GM: Marine natural
products and related compounds in clinical and advanced preclinical
trials. J Nat Prod. 67:1216–1238. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kanagal-Shamanna R, Lehman NL, O’Donnell
JP, Lim MS, Schultz DS, Chitale DA, Bueso-Ramos CE, Medeiros LJ and
Inamdar KV: Differential expression of aurora-A kinase in T-cell
lymphomas. Mod Pathol. 26:640–647. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen H, Xu W, Luo W, Zhou L, Yong W, Chen
F, Wu C, Chen Q and Han X: Upregulation of mdr1 gene is related to
activation of the MAPK/ERK signal transduction pathway and YB-1
nuclear translocation in B-cell lymphoma. Exp Hematol. 39:558–569.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yin P, Wang Y, Qiu Y, Hou L, Liu X, Qin J,
Duan Y, Liu P, Qiu M and Li Q: Bufalin-loaded mPEG-PLGA-PLL-cRGD
nanoparticles: Preparation, cellular uptake, tissue distribution,
and anticancer activity. Int J Nanomed. 7:3961–3969. 2012.
|
|
37
|
Boatright KM and Salvesen GS: Mechanisms
of caspase activation. Curr Opin Cell Biol. 15:725–731. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rathmell JC and Thompson CB: The central
effectors of cell death in the immune system. Annu Rev Immunol.
17:781–828. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qi F, Li A, Inagaki Y, Xu H, Wang D, Cui
X, Zhang L, Kokudo N, Du G and Tang W: Induction of apoptosis by
cinobufacini preparation through mitochondria- and Fas-mediated
caspase-dependent pathways in human hepatocellular carcinoma cells.
Food Chem Toxicol. 50:295–302. 2012. View Article : Google Scholar
|
|
40
|
Schrader A, Meyer K, von Bonin F,
Vockerodt M, Walther N, Hand E, Ulrich A, Matulewicz K, Lenze D,
Hummel M, et al: Global gene expression changes of in vitro
stimulated human transformed germinal centre B cells as surrogate
for oncogenic pathway activation in individual aggressive B cell
lymphomas. Cell Commun Signal. 10:432012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Green MR, Aya-Bonilla C, Gandhi MK, Lea
RA, Wellwood J, Wood P, Marlton P and Griffiths LR: Integrative
genomic profiling reveals conserved genetic mechanisms for
tumorigenesis in common entities of non-Hodgkin’s lymphoma. Genes
Chromosomes Cancer. 50:313–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang Y, Zhang Y, Luan J, Duan H, Zhang F,
Yagasaki K and Zhang G: Effects of bufalin on the proliferation of
human lung cancer cells and its molecular mechanisms of action.
Cytotechnology. 62:573–583. 2010. View Article : Google Scholar : PubMed/NCBI
|
